◼ Archived
Health
🔮 fades ✓
What to know about the new mRNA flu vaccine
Moderna’s mRNA flu shot receives FDA clearance, promising broader immunity as flu season looms.
Gsk
6 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Gsk
This hub groups 6 separate news trends connected to Gsk, spanning July 28, 2026 through September 10, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 85 article observations and 78 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 holds ✗
GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
GSK's mRNA flu vaccine is advancing to Phase 3 trials after outperforming standard shots in Phase 2.
◼ Archived
Business
🔮 fades ✓
There’s a big change for this year’s flu shot: When should you be vaccinated?
GSK's mRNA flu vaccine is advancing to late-stage trials, potentially reshaping annual vaccination strategies.
◼ Archived
Health
🔮 fades ✓
Shingles vaccine linked to 24% lower dementia risk
A shingles vaccine may cut dementia risk by nearly a quarter, sparking hopes for a new preventive tool.
◼ Archived
Health
Finish the fight against HIV/AIDS
Public discourse centers on long-term HIV care advancements as the United States approaches its 250th anniversary.
◼ Archived
Business
🔮 fades ✓
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
GSK’s July 28 earnings beat powers a $2.5 billion three‑year savings drive and an Arizona HQ shift to fast‑track its drug pipeline.